3/6/2007

InterMune says late-stage clinical trial results showed Actimmune did not prolong the lives of those suffering from idiopathic pulmonary fibrosis any better than a placebo. The company has another pulmonary fibrosis drug, pirfenidone, in late-stage trials.

Full Story:
NYTimes.com

Related Summaries